HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Firms Have 15 Days To Respond To Inspection Violations Under New FDA Plan

This article was originally published in The Rose Sheet

Executive Summary

Manufacturers must respond to inspection reports within 15 days to avoid a warning letter, which FDA intends to follow with more concerted regulatory action than in the past, under the agency's revamped enforcement strategy

You may also be interested in...



FDA Seizes More Than $2.7 Mil. Of Tainted Clarcon Sanitizers, Despite Recall

The U.S. Marshals Service seized more than $2.7 million worth of skin sanitizers and ingredients from Clarcon Biological Chemical Laboratory's Roy, Utah facility July 31, even though the firm voluntarily recalled contaminated products in June

What Does FDA Deem A "Serious Adverse Event"? Matrixx Learns The Hard Way

A narrower interpretation of "serious adverse event" - compared with FDA's definition - is costing Matrixx Initiatives at least $10 million dollars with the recall of its intranasal Zicam products - assuming FDA cannot be convinced to reverse its position

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel